Search

Sanofi

Suletud

44.37 1.49

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

43.54

Max

43.72

Põhinäitajad

By Trading Economics

Sissetulek

-1.3B

343M

Müük

1.1B

12B

P/E

Sektori keskmine

23.251

57.002

Aktsiakasum

1.21

Dividenditootlus

9.48

Kasumimarginaal

2.789

Töötajad

74,846

EBITDA

-1B

1.7B

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

+21.23% upside

Dividendid

By Acuity

Dividenditootlus

Sektori keskmine

9.48%

2.22%

Turustatistika

By TradingEconomics

Turukapital

-639M

104B

Eelmine avamishind

42.88

Eelmine sulgemishind

44.37

Sanofi Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

16. aug 2026, 23:51 UTC

Cryptocurrency Declines Reflect Broader Investor Caution Amid Economic Uncertainties and Geopolitical Tensions.

16. aug 2026, 23:51 UTC

Japan's GDP growth data highlights economic recovery amid global caution, while U.S. retail sales drop raises concerns over interest rate hikes and geopolitical tensions impact financial stability.

16. aug 2026, 23:51 UTC

Cryptocurrency and major indices decline amid economic uncertainties, with Bridgewater warning of "crunch time" for capital expenditures and consumer sentiment dropping sharply.

16. aug 2026, 23:51 UTC

Bitcoin and Ethereum decline as major indices show mixed performance amid cautious market sentiment and concerns over capital expenditures.

16. aug 2026, 23:51 UTC

NAHB Housing Market Index for August 2026 set to release with forecast of 33.0 amid cautious sentiment and declining builder confidence.

16. aug 2026, 23:51 UTC

Correlated Moves
Macro News

Bitcoin is lower at $63,022 amid broader market pressures from mixed cryptocurrency movements and recent economic data showing declining U.S. retail sales.

16. aug 2026, 23:41 UTC

Japan's GDP Growth Preliminary Release Expected to Show Modest +0.02% Year-over-Year Increase Amid Mixed Regional Economic Sentiment

16. aug 2026, 23:41 UTC

Japan's Q2 GDP Growth Rate Expected at 0.5% Amid Cautious Market Sentiment and Rising Oil Prices

16. aug 2026, 23:41 UTC

China's July Retail Sales YoY data set for August 17, 2026, forecasts a rise to 1.5%, signaling cautious optimism amid mixed economic indicators.

16. aug 2026, 23:41 UTC

China's Industrial Production YoY data for July 2026 set to release with a forecasted growth rate of 5.0%, amid cautious market sentiment and concerns over declining fixed asset investment.

16. aug 2026, 23:41 UTC

Canada's Retail Sales Ex Autos Expected to Rise 0.5% in June Amid Mixed Economic Sentiment

16. aug 2026, 23:41 UTC

China's Fixed Asset Investment Expected to Decline by 6.2% YoY, Raising Concerns Over Economic Growth

16. aug 2026, 23:31 UTC

U.S. Industrial Production MoM data for July 2026 set to release on August 18, with cautious optimism amid mixed signals and a forecasted increase of 0.3%.

16. aug 2026, 23:21 UTC

Philadelphia Fed Manufacturing Index Set for Release Amid Cautious Optimism and Mixed Economic Signals on August 20, 2026.

16. aug 2026, 23:21 UTC

Canada's New Housing Price Index set for release amid cautious optimism and government infrastructure investments aimed at stabilizing home prices.

16. aug 2026, 23:11 UTC

China's House Price Index YoY release on August 17, 2026, may reveal ongoing pressures in the housing market amid cautious economic indicators and mixed global market performance.

16. aug 2026, 23:02 UTC

Correlated Moves

USD/SEK is lower during after-market hours, continuing a downward trend since Friday. Broader market dynamics are influencing the currency pair's movement.

16. aug 2026, 23:01 UTC

CAD/JPY shows a modest increase in after-hours trading, maintaining an upward trajectory since Friday's close amid a generally positive trading context.

16. aug 2026, 23:01 UTC

Macro News

The US 30Y Treasury Bond Index is trading lower as mixed China economic data raises concerns about global growth prospects. It pulled back from earlier session highs.

16. aug 2026, 23:01 UTC

The US 10Y Treasury Bond Index is lower today, trading down from Friday's close. The index remains in the middle of its one-month range.

16. aug 2026, 23:01 UTC

The CAD/CHF currency pair is higher in after-market hours, reflecting notable strength and unusual activity. It is positioned above its 20-day moving average.

16. aug 2026, 23:01 UTC

GBP/CHF is trading higher during after-market hours, maintaining a steady upward movement since Friday's close. The asset remains near the upper end of its one-month range.

16. aug 2026, 23:01 UTC

Gold and silver are trading higher during Sunday’s session, gaining ground since Friday's close. Key economic data from China is expected tomorrow.

16. aug 2026, 23:01 UTC

Correlated Moves

Gold/NZD is trading higher, supported by rising gold prices against the U.S. dollar and maintaining a position above its 20-day moving average.

16. aug 2026, 23:01 UTC

Correlated Moves

Gold/SGD is higher today, reflecting a modest increase since Friday's close. The asset remains above its 20-day moving average amid rising silver prices.

16. aug 2026, 23:01 UTC

Correlated Moves

Gold/JPY is trading higher, reflecting a slight increase since Friday's close. The asset remains above its 20-day moving average and near its one-month range high.

16. aug 2026, 23:01 UTC

Correlated Moves

Gold/HKD is advancing during the session, reflecting a broader trend as silver also gains. The asset remains above its 20-day moving average.

16. aug 2026, 23:01 UTC

Correlated Moves

Gold/GBP is trading higher, reflecting a modest advance since Friday's close. The asset remains above its 20-day moving average and near recent highs.

16. aug 2026, 23:01 UTC

Correlated Moves

Silver/JPY is higher today, supported by a rise in gold and anticipation of key economic data from China.

16. aug 2026, 23:01 UTC

Correlated Moves

Silver/SGD is rising in the current session, supported by a broader trend in precious metals, with gold also gaining.

Võrdlus sarnastega

Hinnamuutus

Sanofi Prognoos

Hinnasiht

By TipRanks

21.23% tõus

12 kuu keskmine prognoos

Keskmine 53 USD  21.23%

Kõrge 57 USD

Madal 49 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Sanofi 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

3 ratings

0

Osta

3

Hoia

0

Müü

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
help-icon Live chat